One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response

Eur J Intern Med. 2022 May:99:112-115. doi: 10.1016/j.ejim.2021.12.026. Epub 2022 Jan 6.

Authors

Marco Caminati¹, Veronica Batani², Lucia Guidolin², Giuliana Festi³, Gianenrico Senna⁴

Affiliations

¹ Department of Medicine, University of Verona, Verona, Italy. Electronic address: marco.caminati@univr.it.
² Department of Medicine, University of Verona, Verona, Italy.
³ Pneumology Unit, Verona University Hospital, Verona, Italy.
⁴ Department of Medicine, University of Verona, Verona, Italy; Allergy Unit and Asthma Center, University of Verona and Verona University Hospital, Verona, Italy. Electronic address: gianenrico.senna@univr.it.

PMID: 34998664
DOI: 10.1016/j.ejim.2021.12.026

No abstract available

Keywords: Allergic bronchopulmonary aspergillosis; Eosinophils; Mepolizumab; Severe asthma; Steroid-sparing.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Aspergillosis, Allergic Bronchopulmonary* / drug therapy
Humans
Omalizumab
Steroids

Substances

Antibodies, Monoclonal, Humanized
Steroids
Omalizumab
mepolizumab